Competition in viral vector and plasmid DNA manufacturing is becoming increasingly sophisticated as gene and cell therapy programs move closer to commercial production. Manufacturers are not simply competing for production contracts; they are competing on technical capabilities, scalability, quality systems, turnaround times, and their ability to support complex therapeutic programs.
The global industry is projected to grow from USD 7.26 billion in 2025 to approximately USD 29.82 billion by 2035, representing a CAGR of 15.17%. North America held the largest regional position in 2025, accounting for 49% of global revenue.
This environment has encouraged both established manufacturers and specialized biotechnology companies to strengthen their capabilities.
Competitive Landscape in the U.S.
The U.S. has one of the most developed manufacturing environments for viral vectors and plasmid DNA. Precedence Research estimates that the U.S. segment will increase from USD 2.84 billion in 2025 to approximately USD 11.69 billion by 2035.
The competitive landscape includes Thermo Fisher Scientific, Lonza, Catalent, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Aldevron, Oxford Biomedica, Andelyn Biosciences, Resilience, and other specialized organizations.
Large manufacturers generally benefit from established facilities, broad technical capabilities, and experience working with pharmaceutical and biotechnology companies. Specialized organizations, meanwhile, can compete through focused expertise and flexible manufacturing services.
Download Sample https://www.precedenceresearch.com/sample/1012
Why Manufacturing Capacity Is Becoming More Important
One of the biggest competitive factors is the ability to scale production.
A therapy that works successfully in early stage research still needs a reliable manufacturing pathway before it can reach larger clinical studies or commercial production. This creates demand for manufacturers that understand process development, upstream production, downstream purification, analytical testing, and quality control.
Upstream and downstream capabilities are therefore becoming central to company strategies. In the U.S., upstream manufacturing accounted for 60% of the 2025 revenue split in one Precedence Research dataset, compared with 40% for downstream manufacturing.
Companies are also investing in automation and advanced process technologies. These tools can help manufacturers improve production consistency, monitor processes, and reduce development cycles.
North America Remains a Competitive Hub
The competitive environment extends beyond the U.S. North America was valued at USD 2.82 billion in 2025 and is projected to reach USD 10.64 billion by 2035, growing at a CAGR of 14.20%.
The region’s strength comes from its combination of biotechnology companies, research institutions, clinical development activity, manufacturing infrastructure, and investment in advanced therapies.
This creates a relatively strong ecosystem for companies involved in viral vector and plasmid DNA production. At the same time, manufacturers outside North America are also expanding their capabilities, making competition increasingly global.
Buy This Report
You can place an order or ask any questions, please feel free to contact us at [email protected]
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research
driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: https://www.precedenceresearch.com